

11-17-03

1624/4



DOCKET NO.: PH-7211

PATENT

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV323500189US

November 14, 2003
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Examiner:

X. Chen et al.

H. Liu

Serial No.: USSN: 10/043,627

Group Art Unit: 1624

Filed: January 9, 2002

Confirmation No. 6514

For: 1,1-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLOPROTEASES AND TNF- α

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an amendment in the above-identified application.

Fee calculation:


DOCKET NO.: PH-7211

USSN: 10/043,627

- Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$108. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 C.F.R. §1.16 and §1.17 which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.
- Enclosed is a Petition for Extension of Time.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-3791
Date: November 14, 2003


Jing S. Belfield
Jing S. Belfield, Ph.D.
Agent for Applicant
Reg. No. 45,914



DOCKET NO.: PH-7211

PATENT

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV323500189US
Express Mail Label Number

November 14, 2003
Date of Deposit

RECEIVED
DEC 01 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Examiner:

X. Chen et al.

H. Liu

Serial No.: **USSN: 10/043,627**

Group Art Unit: **1624**

Filed: **January 9, 2002**

Confirmation No. **6514**

For: **1,1-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLOPROTEASES AND TNF- α**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

AMENDMENT AND REQUEST FOR RECONSIDERATION

Responsive to the Official Action dated August 20, 2003, Applicants respectfully request reconsideration in view of the following amendments and remarks.

Amendments to the claims are represented by the listing of claims which begins on page 2 of this paper.

Remarks begin on page 27 of this paper.